PRRT2 and breast cancer: At first sight, apparently contradictory to the predictions from our CMap analysis, the PKC activator PMA acts as tumor promoter in cancer and is also implicated in BC progression, with existing studies supporting that PKC inhibition may be useful for treating metastatic BC [32,33] and increasing the chemosensitivity of BC cells [34].